(Information sent by the signatory company)
The state-of-the-art preclinical laboratory consolidates Veranex's commitment to expand its existing preclinical footprint and deepen its therapeutic expertise.
RALEIGH, N.C., Dec. 13, 2023 /PRNewswire/ -- Veranex, provider of the first purpose-built global services platform for the medtech industry, today announced it has acquired T3 Labs, a highly regarded preclinical laboratory located in Atlanta , Georgia. This acquisition solidifies Veranex's commitment to expanding its preclinical presence in North America, deepening its therapeutic expertise and providing customers with greater flexibility.
"Adding T3 Labs to the Veranex family allows us to continue fulfilling our mission of unifying the entire medical technology development process, from concept to commercialization," said Pat Donnelly, CEO of Veranex. "The growth of the preclinical market, increasing regulatory requirements and the need for efficient collaboration between customers and their product development partners make T3 Labs a strategic choice for Veranex and an incredible asset for our customers."
T3 Labs is a leader in preclinical evaluation services in the United States and has a 33,000-square-foot facility with innovative equipment, training facilities and state-of-the-art operating rooms dedicated to research in 12 therapeutic areas. Anchoring Science Square, a growing life sciences center in Atlanta, Georgia, T3 Labs shares strategic community relationships with the Centers for Disease Control and Prevention (CDC), Emory University, Georgia Tech and others. T3 Labs personnel bring deep experience in preclinical medical devices, having contributed to the FDA approval of more than 60 products over the past ten years. T3 Labs complements Veranex PCS France, which has a 25-year track record of providing world-class preclinical services. T3 Labs and Veranex PCS France offer clients comprehensive, turnkey, world-class preclinical service offerings.
T3 Labs is led by Sherry Farrugia, an entrepreneur and executive leader with over 30 years of leadership experience in the medical device and healthcare industry, and Jeff White, DVM, a biomedical operations executive with extensive technology innovation operations experience. medical.
“Joining the Veranex family allows T3 Labs to better serve the medtech community and Science Square,” said Sherry Farrugia. "By combining our expertise and offerings with Veranex's existing preclinical services, we are excited about the impact we can make for our customers and the broader healthcare industry."
Dr. Jeff White added: "Veranex maintains very high standards for the services it provides to its clients, a value that the company and T3 Labs have in common. Together, T3 Labs and Veranex can offer more integrated, valuable and personalized services to the medical technology community. We look forward to our future contributions."
To learn more about Veranex and its revolutionary approach to full-service offerings for medical technology, visit https://veranex.com or follow the company on LinkedIn.
About Veranex
Veranex is the provider of the first global services platform designed specifically for the medical technology industry. From concept to commercialization, Veranex enables companies of all sizes to benefit from accelerated speed to market, controlled development costs, development risk mitigation, and market viability assessment. The company's holistic approach ensures that all key functional areas are addressed with the highest level of expertise and attention to detail. This makes Veranex a trusted partner to help companies deliver innovative products quickly and efficiently, while ensuring the highest level of quality and compliance. Most recently, T3 Labs joined Veranex's growing preclinical presence as its Paris facility celebrated 25 years of advancement in medical innovation. Veranex is backed by Summit Partners, Accelmed, and Lauxera. For more information, visit Veranex.com and follow Veranex on LinkedIn.
Logo - https://mma.prnewswire.com/media/2299653...
View original content: https://www.prnewswire.com/news-releases/veranex-adquiere-t3-labs-proveedor-lider-de-servicios-preclinicos-302014603.html
